Related Experiment Video
Updated: Jul 1, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Anti-heart autoantibodies in familial dilated cardiomyopathy
Alida L P Caforio1, Annalisa Vinci, Sabino Iliceto
1Department of Cardiological, Division of Cardiology, Thoracic and Vascular Sciences, University of Padua, Padua, Italy. alida.caforio@unipd.it
Insights
Autoimmunity is key in myocarditis and dilated cardiomyopathy (DCM), with heart-reactive autoantibodies serving as biomarkers. These autoantibodies can predict DCM development and indicate potential benefits from immunomodulation therapies.
Area of Science:
- Cardiology
- Immunology
- Genetics
Background:
- Myocarditis and dilated cardiomyopathy (DCM) exhibit familial aggregation, suggesting genetic predisposition.
- While gene mutations cause some DCM cases, many remain unexplained due to high heterogeneity.
- Emerging evidence highlights autoimmunity's role in myocarditis and DCM, potentially representing stages of an organ-specific autoimmune disease.
Purpose of the Study:
- To investigate the role of autoimmune markers in familial DCM.
- To determine if known genetic defects in DCM are associated with autoimmune forms of the disease.
- To explore the diagnostic and predictive value of cardiac-specific autoantibodies in myocarditis and DCM.
Main Methods:
- Review of existing literature on familial DCM, myocarditis, and autoimmunity.
- Analysis of diagnostic criteria for autoimmune myocarditis/DCM, including endomyocardial biopsy (EMB) and autoantibody detection.
- Examination of findings from animal models of autoimmune myocarditis/DCM.
Main Results:
- Heart-reactive autoantibodies are found in approximately 60% of familial and non-familial myocarditis/DCM cases and predict disease development in healthy relatives.
- Some autoantibodies demonstrate functional effects on cardiac myocytes in vitro and in animal models.
- Cardiac-specific autoantibodies are disease-specific biomarkers for myocarditis/DCM.
Conclusions:
- Autoimmunity is a significant factor in myocarditis and DCM, particularly in familial cases.
- Cardiac-specific autoantibodies can identify patients and relatives at risk for DCM.
- Immunosuppression or immunomodulation may benefit specific subsets of patients with autoimmune myocarditis/DCM.
Abstract:
Familial aggregation is a feature of myocarditis and dilated cardiomyopathy (DCM). Myocarditis, a clinically polymorphic inflammatory disease of the myocardium, is diagnosed by endomyocardial biopsy (EMB) and may lead to DCM. Mutations in several genes encoding myocyte structural proteins are known monogenic DCM causes, but because of high etiologic and genetic heterogeneity, the gene defects identified so far account for a minority of cases. In the last decade, it has been discovered that autoimmunity plays a pivotal role in myocarditis and DCM that are thought to represent different stages of an organ-specific autoimmune disease in genetically predisposed individuals. None of the available genetic studies in familial DCM has taken into account the autoimmune phenotype markers in the characterization of index patients and relatives, thus it is not known whether or not the described gene defects are involved in the autoimmune form of the disease. In animal models autoimmune myocarditis/DCM can be induced by viral infection, immunization with heart-specific autoantigens, or develop spontaneously in genetically predisposed strains. It may be cell or antibody-mediated; susceptibility is based upon multiple MHC and non-MHC genes. In patients, the diagnosis of autoimmune myocarditis/DCM requires exclusion of viral genome on EMB and detection of serum heart-reactive autoantibodies. They are found in index patients and relatives from about 60% of both familial and non-familial pedigrees and predict DCM development among healthy relatives. Some antibodies have functional effects on cardiac myocytes in vitro, in animal models and possibly in a DCM subset without inflammation, responsive to extracorporeal immunoadsorption. Cardiac-specific autoantibodies, which are shown to be disease-specific for myocarditis/DCM, can be used as biomarkers for identifying patients in whom, in the absence of active infection of the myocardium, immunosuppression and/or immunomodulation may be beneficial and their relatives at risk. Future studies should clarify genetic basis of human autoimmune myocarditis/DCM as well as genotype/immune phenotype correlations.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Rheumatic Heart Disease I: Introduction
Cardiomyopathy I: Introduction and Classification
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy IV: Restrictive Cardiomyopathy

